دورية أكاديمية
أعرض في EDS

A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies.

التفاصيل البيبلوغرافية
العنوان: A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies.
المؤلفون: Härkönen J; Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70210, Finland; Department of Pathology, Hospital Nova of Central Finland, Jyväskylä, 40620, Finland., Pölönen P; Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70210, Finland; Faculty of Health Sciences, Institute of Biomedicine, University of Eastern Finland, Kuopio, 70210, Finland., Deen AJ; Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70210, Finland., Selvarajan I; Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70210, Finland., Teppo HR; Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, 90220, Finland; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, 90570, Finland; Department of Pathology, Oulu University Hospital, Oulu, 90220, Finland., Dimova EY; Faculty of Biochemistry and Molecular Medicine, University of Oulu and Biocenter Oulu, Oulu, 90570, Finland., Kietzmann T; Faculty of Biochemistry and Molecular Medicine, University of Oulu and Biocenter Oulu, Oulu, 90570, Finland., Ahtiainen M; Department of Education and Research, Hospital Nova of Central Finland, Jyväskylä, 40620, Finland., Väyrynen JP; Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, 90220, Finland; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, 90570, Finland; Department of Pathology, Oulu University Hospital, Oulu, 90220, Finland., Väyrynen SA; Department of Internal Medicine, Oulu University Hospital, Oulu, 90220, Finland., Elomaa H; Department of Education and Research, Hospital Nova of Central Finland, Jyväskylä, 40620, Finland; Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, 40100, Finland., Tynkkynen N; Gerontology Research Center (GEREC), Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, 40014, Finland., Eklund T; Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, 40100, Finland., Kuopio T; Department of Pathology, Hospital Nova of Central Finland, Jyväskylä, 40620, Finland; Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, 40100, Finland., Talvitie EM; Department of Genomics, Turku University Hospital and University of Turku, Turku, 20520, Finland., Taimen P; Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, 20520, Finland; Department of Pathology, Turku University Hospital, Turku, 20521, Finland., Kallajoki M; Department of Pathology, Turku University Hospital, Turku, 20521, Finland., Kaikkonen MU; Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70210, Finland., Heinäniemi M; Faculty of Health Sciences, Institute of Biomedicine, University of Eastern Finland, Kuopio, 70210, Finland., Levonen AL; Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70210, Finland. Electronic address: anna-liisa.levonen@uef.fi.
المصدر: Redox biology [Redox Biol] 2023 May; Vol. 61, pp. 102644. Date of Electronic Publication: 2023 Feb 27.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier, B.V Country of Publication: Netherlands NLM ID: 101605639 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2317 (Electronic) Linking ISSN: 22132317 NLM ISO Abbreviation: Redox Biol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam]: Elsevier, B.V., [2013]-
مواضيع طبية MeSH: Carcinoma, Squamous Cell*/genetics , Carcinoma, Squamous Cell*/metabolism , Carcinoma, Squamous Cell*/pathology , NF-E2-Related Factor 2*/metabolism, Female ; Humans ; Carcinoma, Non-Small-Cell Lung/metabolism ; Ligands ; Lung Neoplasms/genetics
مستخلص: The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T cell and macrophage infiltration in squamous malignancies of the lung, head and neck area, cervix and esophagus. Squamous NRF2 overactive tumors comprise a molecular phenotype with SOX2/TP63 amplification, TP53 mutation and CDKN2A loss. These immune cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1 and PD-L1. Based on our functional genomics analyses, these genes represent candidate NRF2 targets, suggesting direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. In addition, we discovered that the negative relationship of NRF2 and immune cells are explained by stromal populations of lung squamous cell carcinoma, and this effect spans multiple squamous malignancies based on our molecular subtyping and deconvolution data.
Competing Interests: Declaration of competing interest The authors declare no potential conflicts interest.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
References: Nat Immunol. 2019 Feb;20(2):163-172. (PMID: 30643263)
JCO Precis Oncol. 2017 Jul;2017:. (PMID: 28890946)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Nat Genet. 2016 Jun;48(6):607-16. (PMID: 27158780)
Sci Rep. 2017 Dec 4;7(1):16878. (PMID: 29203879)
Semin Cancer Biol. 2020 Dec;67(Pt 1):154-167. (PMID: 32905832)
Cancer Cell. 2018 Jul 9;34(1):21-43. (PMID: 29731393)
Oncogene. 2019 Dec;38(50):7473-7490. (PMID: 31444413)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Cancer Res. 2015 Jun 1;75(11):2139-45. (PMID: 25977340)
Science. 2006 Sep 29;313(5795):1960-4. (PMID: 17008531)
Front Physiol. 2017 Aug 24;8:595. (PMID: 28883796)
Adv Cancer Res. 2014;122:281-320. (PMID: 24974185)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Cell Metab. 2021 Jan 5;33(1):110-127.e5. (PMID: 33171124)
Science. 2016 Apr 8;352(6282):227-31. (PMID: 26966191)
Bioinformatics. 2019 Oct 15;35(20):4200-4202. (PMID: 30903160)
Cell Death Dis. 2021 Jan 5;12(1):20. (PMID: 33414469)
Nucleic Acids Res. 2017 Nov 16;45(20):12054. (PMID: 29036333)
Nature. 2019 May;569(7755):270-274. (PMID: 31043744)
Oncogene. 2019 May;38(21):4047-4060. (PMID: 30705400)
Cancer Cell. 2020 Aug 10;38(2):167-197. (PMID: 32649885)
Immunity. 2018 Apr 17;48(4):812-830.e14. (PMID: 29628290)
Cell Metab. 2018 Apr 3;27(4):935-943.e4. (PMID: 29526543)
Cancer Res. 2016 Jul 15;76(14):4136-48. (PMID: 27206847)
Clin Cancer Res. 2021 Feb 1;27(3):877-888. (PMID: 33077574)
Trends Biochem Sci. 2014 Apr;39(4):199-218. (PMID: 24647116)
Nat Rev Cancer. 2018 Mar;18(3):139-147. (PMID: 29326431)
Cell. 2017 Dec 14;171(7):1611-1624.e24. (PMID: 29198524)
Redox Biol. 2013 Jan 18;1:45-9. (PMID: 24024136)
Cell Rep. 2018 Apr 3;23(1):181-193.e7. (PMID: 29617659)
Immunity. 2018 Jan 16;48(1):147-160.e7. (PMID: 29343435)
Cell Rep. 2019 Aug 13;28(7):1860-1878.e9. (PMID: 31412252)
Oncogene. 2018 Sep;37(36):4941-4954. (PMID: 29786078)
J Clin Invest. 2018 Dec 3;128(12):5549-5560. (PMID: 30395540)
Trends Cancer. 2020 Jul;6(7):605-618. (PMID: 32610070)
Nat Protoc. 2020 Apr;15(4):1484-1506. (PMID: 32103204)
Mol Diagn Ther. 2018 Feb;22(1):1-10. (PMID: 29119407)
Clin Cancer Res. 2018 Sep 1;24(17):4242-4255. (PMID: 29769207)
فهرسة مساهمة: Keywords: HLA-I; Interferon gamma; KEAP1; NRF2; PD-L1; Redox; SOX2; Squamous; T cells; TP63
المشرفين على المادة: 0 (Ligands)
0 (NF-E2-Related Factor 2)
تواريخ الأحداث: Date Created: 20230303 Date Completed: 20230320 Latest Revision: 20230329
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10011429
DOI: 10.1016/j.redox.2023.102644
PMID: 36867945
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-2317
DOI:10.1016/j.redox.2023.102644